disease-modifying anti-rheumatoid drugs
Motivations for inadequate persistence with disease modifying anti rheumatic drugs in early rheumatoid arthritis: the patient’s perspective
... Patient’s perception of at least “some difficulty to find arthritis medication” (previously reported as lack of availability at the drug store) and that “arthritis medica- tion is expensive” (lack of financial resources) ...
8
BIOLOGICS: ROLE IN RHEUMATOID ARTHRITIS
... autoimmune disease which is chronic in nature and the exact etiology is ...Biologic disease- modifying antirheumatic drugs (DMARDs) are biologic response modifiers that target a particular ...
9
Effect of disease modifying anti rheumatic drugs on bone structure and strength in psoriatic arthritis patients
... psoriatic disease, duration of PsA, duration of psoriasis, minimal disease activity (MDA) state, disease activity in psoriatic arthritis (DAPSA), Psoriasis Area and Severity Index (PASI), dermatology ...
8
Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease modifying anti rheumatic drugs: a register based study
... thromboembolic disease, chronic respiratory dis- ease, chronic renal insufficiency, depression, malignancy, infections, fractures at sites related to osteoporosis and prosthetic ...
10
A Retrospective Study on Clinical Characteristics of Rheumatoid Arthritis Patients
... of rheumatoid arthritis (RA) patients attending the rheumatology unit in a private ...the disease modifying antirheumatic drugs (DMARDs) as the first line drugs followed by steroids and ...
5
Journal of Applied Pharmaceutical Science
... Nonsteroidal anti-inflammatory drugs have side effects like gastric ...conventional drugs are designed to deliver therapeutic agents specifically to the site of inflammation, therefore avoiding ...
12
Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis
... with rheumatoid arthritis (RA) ...to disease severity and duration [4,5]. Early initiation with disease modifying anti-rheumatic (DMARD) drugs is now a mainstay of therapy, and ...
8
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease modifying anti rheumatic drugs
... a Disease Activity Score 28-C-reactive protein (DAS28-CRP) value of < ...the disease activity was not lowered suffi- ciently to meet these criteria, therapy with bDMARDs was ...and disease-related ...
5
Disease Modifying Anti-rheumatic Drugs (DMARDs)
... Rituximab is a chimeric monoclonal antibody that targets CD20 B lymphocytes. This depletion takes place through cell-mediated and complement dependent cytotoxicity and stimulation of cellapoptosis. Depletion of B ...
7
Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs
... are raising concern about the potential adverse effects of long-term use. Published data currently do not exclude clinically important increased risks, nor do they refute beneficial effects. As per definition, much of ...
15
MANAGEMENT OF RHEUMATOID ARTHRITIS: SPECIAL CONSIDERATION FOR BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS
... control disease activity, reduce joint damage, and improve patients’ quality of ...nonsteroidal anti-inflammatory drugs (NSAIDs) for symptomatic control, followed with a single antirheumatic agent or ...
7
Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes
... Charities; Anti-TNF: anti-tumour necrosis factor drugs; ARUK: Arthritis Research UK; bDMARDs: biologic disease-modifying anti rheumatic drugs; cDMARDs: conventional ...
24
Patient reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease modifying antirheumatic drug treatment
... possible disease activity ...synthetic disease-modifying anti-rheumatic drugs (csDMARDs), es- pecially methotrexate (MTX); if not effective, combining csDMARDs with biological DMARDs ...
10
The underrated prevalence of depression in Japanese patients with rheumatoid arthritis - evidence from a Nationwide survey in Japan
... synthetic disease modifying anti-rheumatic drugs (conven- tional synthetic disease-modifying antirheumatic drugs; csDMARDs) are being ...
8
Natural products in treatment of rheumatoid arthritis
... autoimmune disease associated with articular, extraarticular, and systemic ...non-steroidal anti-inflammatory drugs, disease modifying antirheumatoid drugs, corticosteroids, and ...
8
“Drugs in Rheumatoid Arthritis” by Emily James, Dr. Mathew George, Dr Suseem, India.
... of drugs used in rheumatoid arthritis, various mechanisms of actions of these drugs, alternative systems of medicine in rheumatoid arthritis as well as a brief pathogenesis of the ...of ...
5
Barriers and facilitators to disease modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory based study
... autoimmune disease that is characterized by pain, swollen joints, bone damage, and disability ...are rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis ...with ...
12
<p>A Swedish register-based, long-term inception cohort study of patients with rheumatoid arthritis – results of clinical relevance</p>
... with disease-modifying anti- rheumatic drugs ...active disease had signi fi cantly higher frequency of disability (HAQ ≥ ...in disease activity, suggesting that impaired physical ...
11
Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters
... Results: At study entry, patients were more frequently middle-aged (39.1 ± 13.3 years) and female (88.8 %), as well as more likely to have high disease activity and disability. Over the first 4 years of follow-up, ...
9
Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
... Patients with RA were asked to complete a set of standard- ized self-report questionnaires (Compliance Questionnaire on Rheumatology [CQR], Health Assessment Questionnaire, Short Form-36 questionnaire, 28-joint ...
8